AAMU
ELDN icon

Amundi Asset Management US’s Eledon Pharmaceuticals ELDN Stock Holding History

Amundi Asset Management US’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,078
Closed -$91K – 1615
2018
Q3 		$91K Hold
1,078
– – ﹤0.01% 1525
2018
Q2 		$136K Buy
+1,078
New +$111K ﹤0.01% 1446

Other funds holding ELDN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CSPIA
Cary Street Partners Investment Advisory Richmond, Virginia $494M AUM 27.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi Asset Management US's ELDN Position: Q4 2018 in Review

Amundi Asset Management US sold out of Eledon Pharmaceuticals (ELDN) in Q4 2018, closing a stake of 1,078 shares — an estimated $91K sold.

Amundi Asset Management US first reported a position in ELDN in Q2 2018 and held it in 2 quarters. The position peaked at $136K in Q2 2018. 16 funds tracked by Wall St. Rank hold ELDN as of Q4 2018.

  • Amundi Asset Management US reported no remaining Eledon Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 1,078 Eledon Pharmaceuticals shares in Q4 2018, an estimated $91K.
  • Amundi Asset Management US first reported a position in Eledon Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Amundi Asset Management US's Eledon Pharmaceuticals position peaked at $136K in Q2 2018.
  • 16 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.